Taken together, either pharmacological or genetic inhibition of HDAC6 in human and murine macrophages decreased polarization of macrophages towards tumor-promoting M2 phenotype while retaining the M1 phenotype, suggesting that HDAC6is could be used as therapeutic immunomodulatory agents to control the macrophage phenotype and function. The gene discussed is HDAC6; the disease is neoplasm.